Can GSK Market Breo Ellipta Dosing Advantage Without Adherence Advantage?
Executive Summary
After successful advisory panel – at least for adult asthma indication – Breo Ellipta seems headed for an expanded label, but GSK is still struggling to find some clinical differentiation from its aging twice-daily Advair.
You may also be interested in...
FDA’s Pediatric Data-Extrapolation Policies Questioned At Asthma Panel
Should using adult data to label a product for kids be ‘a judgment call?’ Advisory committee asks whether FDA needs more explicit criteria during review of GSK’s Breo Ellipta.
GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.
Moderna CEO Reminds People About Value Of Government Negotiations At Senate Hearing
Stéphane Bancel also gave conflicting answers for how the company set the cost of its mRNA COVID-19 vaccine as Democratic lawmakers tried to berate Moderna for its coming price hikes. Republicans lawmakers argue against retroactive shaming, saying that if the government wanted to set the eventual commercial price, it should have done that early in negotiations.